Evidence map›Paper›PMID 41760936›Full record

ArticleAnalytical and bioanalytical chemistry2026

Mass spectrometry analysis of young and aged mice and human Alzheimer's disease with Lewy body pathology using on-slide tissue digestion.

Joseph T Nigro, Sayantani Chatterjee, Shira Freilich, Margaret Downs, Alec Candib, Erika Berron, Thor D Stein, Joseph Zaia, Manveen K Sethi

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joseph T NigroDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Sayantani ChatterjeeDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Shira FreilichDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Margaret DownsDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Alec CandibDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Erika BerronDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Thor D SteinDepartment of Pathology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Joseph ZaiaDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Manveen K SethiDepartment of Biochemistry and Cell Biology, Center for Biomedical Mass Spectrometry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. msethi@bu.edu.

Funding

Cerebrovascular Remodeling and Neurodegenerative Changes in Alzheimer's DiseaseR01AG075876 · NIA · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Thor Stein, JOSEPH ZAIA · 2022 to 2026
$3.9M
Boston University Clinical Translational Science Institute Pilot Grant Award 1UL1TR001430BrightFocus Foundation Research Fellowship Award A2020687FNational Institute of Aging R01AG075876NIA NIH HHS R01 AG075876
6 · The paper itself

Abstract

Neurodegenerative disorders such as Alzheimer's disease (AD) and Lewy body disease (LBD) are typically diagnosed after irreversible pathology has developed. Aging, the strongest risk factor, drives molecular changes that predispose the brain to synaptic dysfunction and proteinopathy. Glycosylation and extracellular matrix (ECM) remodeling represent underexplored mechanisms linking aging to neurodegeneration, opening avenues for biomarker discovery, yet mass spectrometry-based glycoproteomics and glycomics studies remain limited. Here, we optimized an on-slide tissue digestion workflow for integrated glycome and proteome profiling from 5-mm brain regions from mice and humans using liquid chromatography data-independent acquisition-tandem mass spectrometry (LC-DIA-MS/MS). This workflow was applied to whole brains from age- and sex-stratified wild-type mice (n = 12) and to human postmortem prefrontal cortex tissue from individuals (n = 14) with brainstem- (n = 8) or limbic-predominant (n = 6) LBD, with or without AD co-pathology. DIA substantially increased protein, glycosylated protein, and ECM coverage by two- to threefold relative to traditional data-dependent acquisition (DDA), while library-free DIA searches further improved detection of low-abundance or region-specific proteins. In aged mouse brains, we observed increased levels of synapse-related proteins-including SYNPR, ZNT3, and HPCA-and enrichment of glutamatergic and postsynaptic pathways, reflecting age-associated synaptic remodeling. Glycomics revealed subtle shifts in the sulfation of chondroitin sulfate (CS) disaccharides with age. In human samples, AD-LBD brainstem tissue exhibited significantly reduced unsulfated, 4-O-sulfated, and total CS levels, along with differential expression of ECM, glycosylated, and mitochondrial proteins, and enrichment of mitochondrial pathways compared with LBD brainstem and AD-LBD limbic tissues. These findings indicate that AD co-pathology exerts a region-specific influence on the proteomic and glycomic landscape of LBD. Collectively, this study establishes a robust DIA-based on-slide digestion platform for high-resolution spatial glycomics and proteomics from minimal tissue, revealing aging- and pathology-specific molecular alterations relevant to neurodegeneration and providing a framework for biomarker discovery.

Indexed as

AgingAlzheimer DiseaseLewy Body DiseaseTandem Mass SpectrometryAgedAged, 80 and overAnimalsBrainChromatography, LiquidFemaleGlycomicsHumansLiquid Chromatography-Mass SpectrometryMaleMiceMice, Inbred C57BLProteomeAgingAlzheimer’s diseaseData-independent acquisitionFormalin-fixed paraffin-embedded tissueFresh frozen tissueGlycomicsLewy body pathologyLiquid chromatographyMass spectrometryOn-slide tissue digestionProteomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.